tion of experimental evidence to clinical studies suggests a benefit in postoperative outcomes. 8 -17 A recent international consensus conference indicated that volatile anaesthetics are among the few drugs/techniques/strategies that might be associated with mortality reduction. 18 They were recommended by the most recent American College of Cardiology/ American Heart Association Guidelines in the setting of coronary artery bypass graft (CABG) surgery, 19 and during noncardiac surgery to maintain general anaesthesia in patients haemodynamically stable at risk for myocardial ischaemia. 20 Cardiac surgery has been the main arena for the comparison between volatile and total i.v. anaesthesia (TIVA) with regard to clinically relevant endpoints. Up to now, the main shortcomings of clinical trials were the small number of patients included, the predominance of single-centre studies, the low-risk isolated CABG surgery setting, the use of surrogate endpoints such as cardiac biomarkers, and short-term followup. 21 22 In a recent network meta-analysis, we confirmed that volatile agents might reduce mortality after cardiac surgery when compared with TIVA (mostly propofol-based TIVA) and that sevoflurane is the most studied volatile agent. 17 If we consider that at least 1 million cardiac operations are performed annually, confirmation of the efficacy of this simple and low-cost treatment would have great clinical impact and significant implications for public health, especially for patients undergoing high-risk cardiac surgery. The objective of this multicentre randomized controlled trial (RCT) was to study the effects of volatile agents in patients undergoing high-risk cardiac surgery with a long-term followup. Our a priori hypothesis was that sevoflurane reduces the composite endpoint of mortality, prolonged intensive care unit (ICU) stay, or both.
Methods

Trial design and participants
We undertook a multicentre, randomized, parallel group, controlled study to determine if sevoflurane has cardioprotective effects compared with propofol-based TIVA in a population of patients planned to undergo high-risk cardiac surgery, defined as combined valvular surgery and CABG. Short-term mortality for this kind of procedures is reported to be 5%. 23 -25 The study was conceived in accordance with the Declaration of Helsinki and its amendments. The study protocol was approved by Ethical Committees of the centres involved and registered with the identifier 2008-001752-43 on Eudra CT (https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-001752-43/IT) and with the identifier NCT00821262 on ClinicalTrials.gov. No change to the methods was made after trial commencement. The study was performed at San Raffaele Scientific Institute and at Azienda Ospedaliero-Universitaria Pisana, in Italy, between September 2008 and June 2011, when the planned number of patients was enrolled. The 1 yr follow-up ended in September 2012. Our report follows the CONSORT 2010 statement guidelines. 26 The methods of the study were previously described. 27 All patients aged 18 yr or more and undergoing combined valvular and coronary surgery were eligible and, if they provided written informed consent, were enrolled. Exclusion criteria were: ongoing acute myocardial infarction, elevated level of circulating cardiac troponin, previous unusual response to sevoflurane (malignant hyperthermia) or propofol (allergic reaction), thoracotomy, use of sulfonylurea, theophylline, or allopurinol.
Randomization and masking
Randomization sequence was stratified by site and generated by a computer by permuted block randomization with a 1:1 allocation and block size of 20. An independent epidemiologist prepared the allocation sequence and concealed it with opaque, sequentially numbered, sealed envelopes. After enrolment, subjects were randomly allocated to the placebo or intervention group by assigning them the envelope with the lowest number. Randomization was performed at the last available moment in the operating theatre. Envelopes were closed and sealed again before the end of surgery. No code break was reported.
Subjects and study personnel, including those involved in ICU management, were blinded to treatment for the duration of the study except for the cardiac anaesthesiologists performing the anaesthesia in the surgical theatre, who were not involved in collecting, entering, or analysing data. To reduce bias, data collection was made by trained observers not otherwise involved in patient care and blinded to the anaesthesia regimen.
Intervention
All subjects were admitted to the cardiac surgery ward before the operation, underwent cardiac surgery with general anaesthesia, and were transferred to the ICU after surgery. All preoperative medications were routinely omitted on the day of surgery. Preoperative b-blockers were continued after operation if permitted by heart rate, arterial pressure, and cardiac index. No other drug was continued routinely or given for cardiac protection.
Premedication was morphine 0. reversed with protamine in a 1:1 ratio. Target mean arterial pressure after CPB was 65 mm Hg. After surgery, subjects were sedated with propofol and transferred to the ICU. After 4 h, weaning from mechanical ventilation began after achievement of haemodynamic stability with no major bleeding, normothermia, adequate level of consciousness and pain control. Postoperative pain relief was provided by morphine and paracetamol.
Transfer from the ICU was performed with the following criteria: peripheral oxygen haemoglobin saturation (Sp O 2 ) ≥94% with an inspired fraction of oxygen (FI O 2 ) ≤0.5 with a facemask, cardiac stability and no haemodynamically significant arrhythmias, chest tube drainage ,50 ml h 21 , urine output .0. , and no seizures. Hospital discharge was performed with the following criteria: haemodynamic and cardiac rhythm stability, clean and dry incisions, apyrexia, normal bowel movement, and independent ambulation and feeding.
Clinical characteristics were collected together with transoesophageal echocardiography data (collected at least 1 day before surgery). Systolic, mean, and diastolic arterial pressure, heart rate, and central venous pressure, and also data from blood gas analysis, were recorded at seven time points: before induction of anaesthesia, before and after CPB, at ICU arrival, and 4, 8, and 12 h later. Blood was collected at four time points: before surgery and 4 h, 1 and 2 days after ICU arrival. Caregivers were interviewed daily for the occurrence of postoperative adverse events. Myocardial infarction was defined as suggested by the Consensus Conference for the Universal Definition of Myocardial Infarction. 28 
Outcome measures
The prespecified main outcome measure was the composite endpoint of death, prolonged ICU stay, or both. Death was defined as death during the post-surgery hospital stay, regardless of the number of days after surgery, while prolonged ICU stay was defined as ICU stay .2 days using the above transfer criteria. To overcome bias organizational factors, the times of fitness for criteria of discharge from the ICU were collected and analysed.
Secondary outcome measures were: cardiac troponin release, incidence of perioperative myocardial infarction (cardiac biomarker values .5 times the 99th percentile of the normal reference range during the first postoperative 72 h when associated with new pathological Q-waves or new left bundle branch block or electrocardiogram or occlusion of a new graft or a native coronary artery at angiography with new loss of viable myocardium), 28 time on mechanical ventilation (h), and postoperative hospital stay (days). Neurological damage was classified as follows: type I neurological damage was defined as fatal or non-fatal stroke, transient ischaemic attack, stupor, or coma at discharge; type II neurological damage was defined as intellectual function worsening, confusion, agitation, disorientation, memory deficit, or seizures. 29 Renal injury was classified according to the RIFLE criteria.
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Statistical analysis
Sample size calculation was based on a two-sided a-error of 0.05 and a power of 80%. We expected 60% of subjects with a composite endpoint of death, prolonged ICU stay (.2 days), or both in the control group and 40% of patients in the treatment group, with a calculated sample size of 93 subjects per group. Therefore, we planned to enrol 1200 subjects.
Data were stored in an electronic database and analysed using SAS software version 9 (SAS Institute, North Carolina, USA), and are expressed as number (%) or mean (standard deviation) or as medians (25th and 75th percentiles). Data were analysed according to the intention-to-treat principle and following a pre-established analysis plan. Dichotomous data were compared with the two-tailed x 2 test, using the Yates 
Results
The number of patients screened for enrolment, the number of subjects enrolled, and their fate in the study are summarized in Figure 1 . No subject retired or was withdrawn from the study. One subject randomized to the sevoflurane group received propofol during CPB by mistake. All subjects were included in efficacy analyses conducted according to the intention-to-treat principle.
Baseline characteristics are presented in Table 1 , and were balanced between the two treatment groups. Intraoperative data, intraoperative and postoperative vital parameters, and other outcome data are listed in Tables 2 and 3 . Troponin T, creatinine, and blood natriuretic peptide values before and after surgery are presented in Figure 2 .
The primary endpoint occurred in 36 patients (36%) in the control group and 41 patients (41%) in the intervention group (relative risk 1.14, 95% confidence interval 0.8-1.62; P¼0.5). There was no difference between the two groups regarding secondary endpoints (Table 3) .
At follow-up, no difference was found between groups in allcause mortality at 30 days [seven subjects (7%) died in the control group and eight subjects (8%) died in the intervention group, P¼0.8; relative risk 1.14 (95% confidence interval 0.43 -3.03)] and at 1 yr [11 subjects (11%) died in the control group and 11 subjects (11%) died in the intervention group, P¼0.9; relative risk 1 (95% confidence interval 0.45 -2.19)], and in terms of new hospitalizations and adverse cardiac events (Table 3) .
Discussion
This is the first multicentre RCT of volatile anaesthesia compared with TIVA performed in patients undergoing high-risk cardiac surgery with long-term follow-up. There was no difference between groups in the composite primary endpoint of death, prolonged ICU stay, or both; length of hospital stay; and 30 day and 1 yr mortality.
The first important limitation of our study is that the expected incidence of the primary outcome and the expected absolute risk reduction in the study group, on which the power calculation was based, might be considered excessive, rendering the study vulnerable to type II errors. The second limitation of our study is that cardiac anaesthesiologists performing the anaesthesia in the surgical theatre were not blinded to the treatment, but this potential source of bias was minimized by the fact that they were not in charge of post-surgery patient care and monitoring, whereas subjects and all investigators involved in study and data recording, monitoring, and analyses were blinded to treatment allocation. Another limitation of the study is that it was not powered to detect a difference in mortality at 30 days and at the 1 yr follow-up. It is possible that possible beneficial effects of sevoflurane are diluted when valve surgery is included and the study does not exclude the effectiveness of sevoflurane as a cardioprotective agent in a broader cardiac surgical population. The strength of our study in relation to other studies is that, even though it is not sufficiently powered, it is the first multicentre RCT on patients undergoing high-risk cardiac surgery. This multicenter RCT was designed to reduce biases associated with single-centre studies. 31 Secondly, we identified and targeted a group of patients undergoing high-risk cardiac surgery in whom the benefit could, theoretically, have been more relevant. We hypothesized that, in this group of patients, the possible cardioprotective effect of sevoflurane would result not only in a statistically significant, but not relevant to outcome, reduction in cardiac troponin release, but also in a reduction of the composite primary endpoint of death, prolonged ICU stay, or both. Our present findings do not confirm previous data suggesting that volatile agents might have beneficial effects that translate into a reduction in ICU stay and mortality, 11 -15 17 and amelioration of surrogate endpoints including cardiac Volatile vs TIVA in high-risk cardiac surgery biomarker release. 11 The first paper to suggest a survival difference was a meta-analysis of RCTs performed in cardiac surgery comparing desflurane or sevoflurane with TIVA. 11 Similar results were suggested by a meta-analysis of RCTs comparing isoflurane with TIVA when only high-quality studies performed in cardiac surgery were considered. 13 An RCT reported large 1 yr mortality differences between sevoflurane, desflurane, and TIVA in CABG surgery patients, even if the high mortality rates observed in the TIVA group could be attributed, at least in part, to chance effects. 15 A retrospective study suggested a beneficial survival effect with the use of sevoflurane in low-risk CABG surgery. 32 A meta-regression on more than 34 000 CABG procedures showed that the 30 day mortality was lower in patients receiving volatile anaesthetics. 32 Finally, we recently performed an updated network meta-analysis comparing desflurane, isoflurane, sevoflurane, and TIVA, 17 and, including 38 RCTs with survival data in this setting, found that halogenated anaesthetics were associated with a mortality reduction when compared with TIVA at the longest follow-up available [25/1994 (1.3%) Volatile vs TIVA in high-risk cardiac surgery BJA in the TIVA group, P¼0.004]. This Bayesian network metaanalysis showed that sevoflurane (odds ratio¼0.31, 95% credible interval 0.14-0.64) and desflurane (odds ratio¼0.43, 95% credible interval 0.21-0.82) were associated individually with mortality reduction compared with TIVA (.60% of the time propofol-based TIVA). Notably, most studies performed so far on this topic were single-centre, include low-risk CABG surgery and have a short-term follow-up. Our study does not confirm our hypothesis that in high-risk cardiac surgery, volatile anaesthetics are superior to propofol-based TIVA using significant postoperative outcomes such as prolonged ICU stay, mortality, or both. Therefore, the promising beneficial effects of volatile anaesthetics, if any, might be limited to the isolated low-risk CABG surgery setting, and do not apply to high-risk cardiac surgery. Notably, patients undergoing high-risk cardiac surgery are those who would benefit more from improvement in cardioprotective strategies. Since the cardiac protective properties of volatile agents are well established in cellular and preclinical studies, our negative findings could be attributed to the absence of these cardiac protective properties in patients undergoing high-risk cardiac surgery, since in these patients, the mechanisms of cardiac damage might only in part be due to ischaemia/reperfusion injury.
Conclusions
This multicentre RCT study did not demonstrate any difference between sevoflurane anaesthesia and propofol TIVA on the composite endpoint of prolonged ICU stay, mortality, or both in patients undergoing high cardiac surgery.
